Additionally, in hu-CD34+ and C57BL/6 mice, APG-2575 treatment consistently elevated the level of CD86 while reducing that of CD206 in tumor-infiltrating macrophages (Fig. 4H–K), as determined by flow cytometry, accompanied by upregulation of CD86 and downregulation of CD206 in tumor tissues, as detected by IHC (Fig. 4L–O). This evidence concerns the gene CD86 and neoplasm.